Revvityブログ
発見から治療までのイノベーションを促進
 
     
    
            
        Latest
      
    
    Optimizing functional genomics research tools by aligning their design with the ongoing evolution of the genome.
Functional Genomic Screening 
October 30, 2025  -  3  min read
       
      Small Molecule Drug Discovery
        Improving drug safety through cardiotoxicity assessment.
            April 29, 2024 -
            2 min read
          
          
         
       
      NGS
        Existing depletion technologies for Next-Generation Sequencing (NGS).
            April 26, 2024 -
            2 min read
          
          
         
      Cancer
        Fluorescence imaging is comparable to PET in early detection of tumor metabolism.
            April 25, 2024 -
            4 min read
          
          
         
      Cancer
        The top 7 attributes of cell line-derived reference standards for oncology assays.
            April 25, 2024 -
            2 min read
          
          
         
      Cell and Gene Therapy
        The future of cell and gene therapy: Revvity at ASGCT.
            April 23, 2024 -
            2 min read
          
          
         
      NGS
        Limitations associated with the lack of data analysis tools in metagenomics.
            April 16, 2024 -
            2 min read
          
          
         
      Cancer, Drug Development, Disease Research
        Why use fluorescent probes in your in vivo imaging studies?
            April 9, 2024 -
            3 min read
          
          
         
      Physiological Model Solutions, Cancer
        Overcoming the challenges of 3D immune cell-killing assays.
            April 5, 2024 -
            2 min read
          
          
         
      Physiological Model Solutions, Automation
        Making organoids ready for screening.
            April 5, 2024 -
            3 min read
          
          
         
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                  